|Day Low/High||14.20 / 14.92|
|52 Wk Low/High||4.67 / 25.07|
Here's a window into what institutional investors may be doing and how to profit from that.
America's veterans, military personnel and their families provided access to non-invasive, at-home colon cancer screening option without copay
Exact Sciences (EXAS) stock is gaining on Monday after the National Committee for Quality Assurance updated its guidelines on colorectal cancer screening tests.
Cologuard offers opportunity for health plans, systems & providers to improve quality ratings
Here's a look at two stocks that are trending higher and two that are ripe for short-selling.
The most recent short interest data was recently released for the 08/31/2016 settlement date, and EXACT Sciences Corp. is one of the most shorted stocks of the Russell 3000, based on 8.37 "days to cover" versus the median component at 6.39.
These four stocks are looking strong technically, either breaking out or approaching breakout levels.
Which stocks have had the highest gains following earnings? Bespoke Investment came up with a list of the 40 stocks that had the best performance on their earnings reaction days.
Positive medical policies from health plans that collectively insure 18 million people
Here are four biotech and technology stocks showing strong technical momentum.
Exact Sciences (EXAS) announced today that it would be offering 8.5 million shares of common stock.
Exact Sciences Corporation (NASDAQ: EXAS) today announced an agreement to sell 7,000,000 shares of its common stock to Jefferies LLC, Robert W.
Trade-Ideas LLC identified Exact (EXAS) as a strong on high relative volume candidate
Exact Sciences (EXAS) is climbing today after the company reports better-than-expected 2016 second quarter earnings.
Updated HEDIS Measures Would Align with Final USPSTF Recommendations
Trade-Ideas LLC identified Exact (EXAS) as a post-market leader candidate
Shares of Exact Sciences (EXAS) are gaining after reports that the company may be acquired by Illumina (ILMN).
Trade-Ideas LLC identified Exact (EXAS) as a weak on high relative volume candidate